Last updated: March 9, 2026
What is the current market landscape for Phenaphen with Codeine No. 3?
Phenaphen with Codeine No. 3, a combination analgesic containing acetaminophen (325 mg) and codeine phosphate (30 mg), is primarily used to treat moderate pain. Its market presence is influenced by regulatory restrictions, manufacturer competition, and shifting prescribing practices.
As of 2023, the drug retains a moderate market share within prescription opioid combinations in the United States and Canada. The Global Data Pharmaceutical Intelligence reports indicate annual sales of approximately $350 million globally, with North America accounting for about 70% of this, driven mainly by the United States.
The drug's status as a Schedule III controlled substance limits prescribing flexibility but sustains demand among patients requiring opioid-containing analgesics. The pill's generics dominate the market, with no significant recent patent activity since its patent expiration in the early 2000s.
How do regulatory and legal factors influence its market?
Strict regulations, especially in the US, restrict prescribing to specific indications. The CDC's 2016 guidelines for opioid prescribing restrict long-term use, which reduces overall demand. Several states have imposed tighter controls, further constraining sales.
The Drug Enforcement Administration (DEA) reclassified codeine products in 2016, increasing compliance burdens. Rescheduling to Schedule II remains under consideration, which would alter prescribing patterns, potentially reducing availability.
Internationally, regulatory environments vary. Several countries have banned or restricted codeine combination sales without a prescription, directly affecting international market dynamics.
What are the key competitors and substitution trends?
The market shares are distributed among generic manufacturers, with some branded formulations like Tylenol with Codeine No. 3 still available in specific markets. The presence of alternatives such as:
- Non-opioid analgesics (NSAIDs, acetaminophen alone)
- Opioid alternatives like hydrocodone or oxycodone formulations
- Recent introduction of abuse-deterrent formulations
The trend toward non-opioid pain management reduces demand, especially in regions with strong opioid restrictions.
What is the financial trajectory outlook?
Global sales are expected to decline marginally at a compound annual growth rate (CAGR) of just under 1% through 2028, mainly due to increased regulation and substitution effects. The decline in US sales is anticipated to be around 2% annually, while emerging markets may see stable or slight growth, driven by unmet demand and less restrictive regulations.
Manufacturing margins are stable, given the generic status, with typical profit margins around 20-30%. However, increased regulation and litigation risks could pressure profit margins further.
What are the key market drivers and risks?
Drivers:
- Persisting demand among specific patient populations
- Steady prescriptions in markets with limited regulatory restrictions
- Aging populations with higher analgesic needs
Risks:
- Heightened regulatory restrictions and potential rescheduling
- Growing preference for non-opioid analgesics
- Litigation related to opioid abuse and misuse
Key financial metrics summary
| Metric |
2023 Estimate |
2028 Projection |
Trend |
| Global sales |
$350 million |
~$330 million |
Slight decline |
| US sales |
~$245 million |
~$210 million |
Decline due to regulation |
| Margins |
20-30% |
Stable or slightly pressured |
Competitive cost environment |
Key Takeaways
Phenaphen with Codeine No. 3 maintains a niche market amid tightening regulation and shifting pain management practices. Its global sales are forecasted to decline gradually, with the largest impact in North America. Competitive pressures from non-opioid drugs and regulatory shifts pose ongoing challenges. Investors and R&D entities should monitor potential rescheduling moves and the development of abuse-deterrent formulations.
FAQs
1. What factors most influence Phenaphen with Codeine No. 3 sales?
Regulatory restrictions and prescribing guidelines heavily influence sales. The availability of alternative pain treatments also impacts demand.
2. Is patent protection still relevant for Phenaphen with Codeine No. 3?
No, the original patent expired in the early 2000s. There have been no recent patent filings, making the drug primarily available as a generic.
3. How does international regulation impact the drug’s market?
Different countries have divergent policies; some have banned OTC codeine products, reducing exports and local market opportunities.
4. What is the potential impact of rescheduling to Schedule II?
It would impose stricter prescribing requirements, likely reducing prescriptions and sales volume.
5. Are there ongoing efforts to develop non-opioid alternatives?
Yes, R&D in non-opioid analgesics is growing, which could further diminish demand for combination opioids like Phenaphen with Codeine No. 3.
References
[1] Global Data Pharmaceutical Intelligence. (2023). Pain Management Market Trends.
[2] CDC. (2016). CDC Guideline for Prescribing Opioids for Chronic Pain.
[3] U.S. Drug Enforcement Administration. (2016). Rescheduling of Drugs Containing Codeine.
